Moberg Pharma AB (publ)
STO:MOB

Watchlist Manager
Moberg Pharma AB (publ) Logo
Moberg Pharma AB (publ)
STO:MOB
Watchlist
Price: 9.22 SEK 1.6% Market Closed
Market Cap: 441.5m SEK

Net Margin
Moberg Pharma AB (publ)

-1 954.8%
Current
-3 020%
Average
5.1%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 954.8%
=
Net Income
-251.4m
/
Revenue
12.9m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
SE
Moberg Pharma AB (publ)
STO:MOB
430.5m SEK
-1 955%
US
Eli Lilly and Co
NYSE:LLY
725.7B USD
23%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
-4%
US
Johnson & Johnson
NYSE:JNJ
369.6B USD
24%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
35%
CH
Roche Holding AG
SIX:ROG
212.9B CHF
14%
CH
Novartis AG
SIX:NOVN
188.6B CHF
24%
UK
AstraZeneca PLC
LSE:AZN
165.9B GBP
14%
US
Merck & Co Inc
NYSE:MRK
195.3B USD
27%
IE
Endo International PLC
LSE:0Y5F
163.5B USD
-126%
US
Pfizer Inc
NYSE:PFE
131.7B USD
13%

Moberg Pharma AB (publ)
Glance View

Market Cap
430.5m SEK
Industry
Pharmaceuticals

Moberg Pharma AB is a pharmaceutical company, which engages in the development and commercialization of medical products. The company is headquartered in Bromma, Stockholm. The company went IPO on 2011-05-26. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The firm collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. The company is active in more than 35 countries, and operates, among others, through Alterna LLC. The company also owns three Over-The-Counter (OTC) brands in the United States.

MOB Intrinsic Value
24.59 SEK
Undervaluation 63%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-1 954.8%
=
Net Income
-251.4m
/
Revenue
12.9m
What is the Net Margin of Moberg Pharma AB (publ)?

Based on Moberg Pharma AB (publ)'s most recent financial statements, the company has Net Margin of -1 954.8%.

Back to Top